AG
SYRS

Artal Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Artal Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,505,013
Closed -$12.9M – 108
2024
Q2 		$12.9M Hold
2,505,013
– – 0.33% 35
2024
Q1 		$13.4M Hold
2,505,013
– – 0.34% 36
2023
Q4 		$19.5M Buy
2,505,013
+1,029,269
+70% +$3.53M 0.65% 23
2023
Q3 		$5.83M Hold
1,475,744
– – 0.25% 55
2023
Q2 		$4.65M Hold
1,475,744
– – 0.14% 69
2023
Q1 		$3.94M Buy
1,475,744
+11,915
+0.8% +$46.2K 0.23% 66
2022
Q4 		$5.25M Hold
1,463,829
– – 0.29% 60
2022
Q3 		$9.43M Buy
1,463,829
+1,063,829
+266% +$8.64M 0.4% 44
2022
Q2 		$3.85M Buy
400,000
+50,000
+14% +$468K 0.21% 67
2022
Q1 		$4.17M Buy
350,000
+50,000
+17% +$894K 0.17% 88
2021
Q4 		$9.78M Buy
300,000
+100,000
+50% +$4.05M 0.27% 70
2021
Q3 		$8.94M Buy
200,000
+30,000
+18% +$1.46M 0.2% 85
2021
Q2 		$9.27M Buy
170,000
+67,500
+66% +$4M 0.19% 91
2021
Q1 		$7.67M Buy
102,500
+27,500
+37% +$2.86M 0.14% 110
2020
Q4 		$8.14M Buy
75,000
+28,450
+61% +$2.6M 0.17% 94
2020
Q3 		$4.12M Sell
46,550
-2,450
-5% -$278K 0.1% 102
2020
Q2 		$5.22M Sell
49,000
-1,614
-3% -$145K 0.15% 104
2020
Q1 		$3M Buy
+50,614
New +$3.43M 0.13% 93

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Artal Group's SYRS Position: Q3 2024 in Review

Artal Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 2,505,013 shares — an estimated $12.9M sold.

Artal Group first reported a position in SYRS in Q1 2020 and held it in 18 quarters. The position peaked at $19.5M in Q4 2023. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Artal Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 2,505,013 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $12.9M.
  • Artal Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 18 quarters.
  • Artal Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $19.5M in Q4 2023.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.